Protara Therapeutics, Inc. (TARA) Income Statement
TARA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTARA revenue and net income
TARA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TARA quarterly EPS vs estimates
Protara Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.37).
TARA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $362,000 | $332,000 | $341,000 | $247,000 | $1.2M | $196,000 | $16,000 | $115,000 | $148,000 | $123,000 |
| Gross profit | −$362,000 | −$332,000 | −$341,000 | −$247,000 | −$1.2M | −$196,000 | −$16,000 | −$115,000 | −$148,000 | −$123,000 |
| Research & development | $42.6M | $31.7M | $24.8M | $16.8M | $21.1M | $11.9M | $6.4M | $15.5M | $21.7M | $18.9M |
| Sales, general & admin | $21.9M | $17.4M | $18.8M | $20.7M | $26.4M | $22.5M | $8.8M | $10.6M | $8.5M | $10.0M |
| Total operating expenses | $64.2M | $49.2M | $43.3M | $67.1M | $47.5M | $34.2M | $15.3M | $26.1M | $30.2M | $28.6M |
| Operating income | −$64.5M | −$49.2M | −$43.6M | −$67.1M | −$47.5M | −$34.4M | −$15.3M | −$26.1M | −$30.4M | −$28.7M |
| Interest income | $6.3M | $4.1M | $3.0M | $2.2M | $2.0M | $500,000 | $262,000 | $436,000 | $259,000 | $193,000 |
| Interest expense | — | $4.2M | — | $1.1M | $1.7M | $34,000 | $0 | $0 | $259,000 | $193,000 |
| Income before taxes | −$57.4M | −$44.6M | −$40.4M | −$66.0M | −$47.3M | −$34.0M | −$15.0M | −$25.4M | −$30.0M | −$28.5M |
| Income taxes | — | — | −$341,000 | −$1.1M | −$117,000 | −$466,000 | −$262,000 | $5.4M | $657,000 | $372,000 |
| Net income | −$57.4M | −$44.6M | −$40.4M | −$66.0M | −$47.3M | −$34.0M | −$15.0M | −$25.4M | −$30.0M | −$28.5M |
| EBITDA | −$57.1M | −$44.3M | −$40.1M | −$64.6M | −$45.4M | −$33.8M | −$7.8M | −$20.6M | −$29.8M | −$28.4M |
| EPS (diluted) | −$1.33 | −$2.35 | −$3.57 | −$3.99 | −$4.21 | −$4.73 | −$30.15 | −$45.60 | −$69.20 | −$69.20 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $332,000 | $0 | $0 | $0 | $1.2M | $0 |
| Cost of revenue | — | $90,000 | $93,000 | $88,000 | $98,000 | $83,000 | $166,000 | $84,000 | $83,000 | $83,000 | $107,000 | $107,000 |
| Gross profit | — | −$90,000 | −$93,000 | −$88,000 | −$98,000 | −$83,000 | $166,000 | −$84,000 | −$83,000 | −$83,000 | $1.1M | −$107,000 |
| Research & development | $17.0M | $13.5M | $13.1M | $9.6M | $10.8M | $9.1M | $9.5M | $8.1M | $6.4M | $7.7M | $6.4M | $6.2M |
| Sales, general & admin | $6.4M | $6.1M | $6.0M | $5.2M | $5.8M | $5.0M | $4.8M | $4.3M | $4.3M | $4.1M | $4.8M | $4.5M |
| Total operating expenses | $23.3M | $19.5M | $19.1M | $14.8M | $16.6M | $14.1M | $14.3M | $12.3M | $10.7M | $11.8M | $11.0M | $10.7M |
| Operating income | −$23.3M | −$19.6M | −$19.1M | −$14.8M | −$16.6M | −$14.1M | −$14.3M | −$12.3M | −$10.7M | −$11.9M | −$11.0M | −$10.7M |
| Interest income | $1.6M | $1.8M | $1.5M | $1.5M | $1.6M | $1.7M | $1.1M | $1.1M | $1.1M | $747,000 | $814,000 | $840,000 |
| Interest expense | — | $1.8M | — | $1.5M | $1.6M | $1.7M | — | — | — | — | $687,000 | — |
| Income before taxes | −$21.7M | −$17.8M | −$17.3M | −$13.3M | −$15.0M | −$11.9M | −$12.8M | −$11.2M | −$9.5M | −$11.1M | −$10.2M | −$9.9M |
| Income taxes | — | — | — | — | — | — | — | — | — | $39,724 | $1.6M | −$107,000 |
| Net income | −$21.7M | −$17.8M | −$17.3M | −$13.3M | −$15.0M | −$11.9M | −$12.8M | −$11.2M | −$9.5M | −$11.1M | −$10.2M | −$9.9M |
| EBITDA | −$21.6M | −$17.7M | −$17.2M | −$13.2M | −$14.9M | −$11.8M | −$12.7M | −$11.1M | −$9.4M | −$11.0M | −$10.1M | −$9.8M |
| EPS (diluted) | −$0.36 | −$0.31 | −$0.38 | −$0.31 | −$0.35 | −$0.29 | −$0.43 | −$0.50 | −$0.45 | −$0.97 | −$0.90 | −$0.87 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 91.1% | — |
| Operating margin | — | — | — | — | — | — | −4,310.8% | — | — | — | −914.0% | — |
| Net margin | — | — | — | — | — | — | −3,846.1% | — | — | — | −846.1% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TARA's financial statements (latest annual report filed March 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TARA financial results
Protara Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $57.4 million. Diluted earnings per share came to −$1.33.
See the TARA stock overview for the latest quote and news, or the TARA chart for price history and technical indicators.
TARA income statement FAQ
Does Protara Therapeutics have revenue?
Protara Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Protara Therapeutics profitable?
No. Protara Therapeutics reported a net loss of $57.4 million in fiscal 2025.
How much does Protara Therapeutics spend on research and development?
Protara Therapeutics spent $42.6 million on research and development in fiscal 2025.
What are Protara Therapeutics's earnings per share?
Protara Therapeutics earned $-1.33 per diluted share in fiscal 2025, compared with $-2.35 a year earlier.
When will Protara Therapeutics report its next earnings?
Protara Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Protara Therapeutics's fiscal year end?
Protara Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 10, 2026.